-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo Therapeutics Publishes Presentation on Interim LX2020 Trial Data in PKP2 Cardiomyopathy

PUBT·11/16/2026 12:05:59
Listen to the news
Lexeo Therapeutics Publishes Presentation on Interim LX2020 Trial Data in PKP2 Cardiomyopathy
  • Lexeo Therapeutics published a presentation of interim Phase 1/2 HEROIC-PKP2 trial data evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy.
  • Seven high-dose participants showed an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) burden; premature ventricular contraction burden fell 44%.
  • LX2020 was generally well tolerated across 10 participants; one previously disclosed Grade 3 serious adverse event involved sustained ventricular tachycardia.
  • The FDA is open to guideline-defined NSVT as a primary surrogate endpoint supporting potential accelerated approval of LX2020.
  • Pivotal study design finalization is expected in the first half of 2027, with trial initiation under the accelerated approval pathway in the second half.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.